Literature DB >> 28425041

Familial amyloid cardiomyopathy masquerading as chronic Guillain-Barre syndrome: things are not always what they seem.

Die Hu1, Ling Liu1, Shuguang Yuan2, Yuhong Yi1, Daoquan Peng3.   

Abstract

Familial amyloid cardiomyopathy is a challenging condition that mimics many other diseases, particularly in patients with pronounced neurological presentations and unexplained or equivocal cardiac abnormalities. In this case, a 57-year-old man was admitted for outpatient cardiological evaluation of progressive right heart failure and limb paraesthesias. The patient presented with hypertension, chronic Guillain-Barre syndrome, and sick sinus syndrome. Transthoracic echocardiograms showed a thickened ventricular wall and enlarged atrium. Tissue Doppler showed a restrictive filling pattern. Transthyretin (TTR)-associated amyloidosis, which was revealed by abdominal fat-pad biopsy and DNA analysis, explained the concurrence of independent pathological features, including neuropathy and cardiac involvement. Genetic testing identified a G > T mutation in exon 4 of the transthyretin (TTR) gene. This mutation resulted in the alanine-to-serine substitution at amino acid position 117. Moreover, genetic testing confirmed that the patient's asymptomatic son carried the same amyloidogenic TTR mutation. Given these findings, the diagnosis of familial amyloid cardiomyopathy, which was misdiagnosed as chronic Guillain-Barre syndrome, was proposed.

Entities:  

Keywords:  chronic Guillain-Barre syndrome; sick sinus syndrome; transthyretin (TTR) cardiac amyloidosis

Mesh:

Substances:

Year:  2017        PMID: 28425041     DOI: 10.1007/s11684-017-0516-9

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  5 in total

Review 1.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

Review 2.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

3.  Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy.

Authors:  N Tachibana; T Tokuda; K Yoshida; T Taketomi; M Nakazato; Y F Li; Y Masuda; S Ikeda
Journal:  Amyloid       Date:  1999-12       Impact factor: 7.141

Review 4.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

5.  Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy.

Authors:  Thibaud Damy; Mathew S Maurer; Claudio Rapezzi; Violaine Planté-Bordeneuve; Onur N Karayal; Rajiv Mundayat; Ole B Suhr; Arnt V Kristen
Journal:  Open Heart       Date:  2016-02-08
  5 in total
  2 in total

1.  Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study.

Authors:  Kang Du; Fan Li; Hui Wang; Yuanfeng Miao; He Lv; Wei Zhang; Zhaoxia Wang; Yun Yuan; Lingchao Meng
Journal:  Ann Clin Transl Neurol       Date:  2021-03-19       Impact factor: 4.511

2.  Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China.

Authors:  Xinyue He; Zhuang Tian; Hongzhi Guan; Shuyang Zhang
Journal:  Orphanet J Rare Dis       Date:  2022-09-02       Impact factor: 4.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.